AU639033B2 - Imidazo(4,5-b)quinolinyloxyalkanoic acid amines with enhanced water solubility - Google Patents

Imidazo(4,5-b)quinolinyloxyalkanoic acid amines with enhanced water solubility

Info

Publication number
AU639033B2
AU639033B2 AU65679/90A AU6567990A AU639033B2 AU 639033 B2 AU639033 B2 AU 639033B2 AU 65679/90 A AU65679/90 A AU 65679/90A AU 6567990 A AU6567990 A AU 6567990A AU 639033 B2 AU639033 B2 AU 639033B2
Authority
AU
Australia
Prior art keywords
imidazo
water solubility
enhanced water
acid amines
quinolinyloxyalkanoic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU65679/90A
Other versions
AU6567990A (en
Inventor
Nicholas A. Meanwell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AU6567990A publication Critical patent/AU6567990A/en
Application granted granted Critical
Publication of AU639033B2 publication Critical patent/AU639033B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU65679/90A 1989-11-01 1990-10-31 Imidazo(4,5-b)quinolinyloxyalkanoic acid amines with enhanced water solubility Ceased AU639033B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US430228 1989-11-01
US07/430,228 US4943573A (en) 1989-11-01 1989-11-01 Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility

Publications (2)

Publication Number Publication Date
AU6567990A AU6567990A (en) 1991-05-23
AU639033B2 true AU639033B2 (en) 1993-07-15

Family

ID=23706624

Family Applications (1)

Application Number Title Priority Date Filing Date
AU65679/90A Ceased AU639033B2 (en) 1989-11-01 1990-10-31 Imidazo(4,5-b)quinolinyloxyalkanoic acid amines with enhanced water solubility

Country Status (20)

Country Link
US (1) US4943573A (en)
EP (1) EP0426180A3 (en)
JP (1) JPH03169880A (en)
KR (1) KR910009705A (en)
CN (1) CN1025999C (en)
AU (1) AU639033B2 (en)
CA (1) CA2027935A1 (en)
EG (1) EG19372A (en)
FI (1) FI92697C (en)
HU (1) HU209305B (en)
IE (1) IE61579B1 (en)
IL (1) IL96167A (en)
MY (1) MY105308A (en)
NO (1) NO175531C (en)
NZ (1) NZ235868A (en)
OA (1) OA09323A (en)
PT (1) PT95765A (en)
RU (1) RU2041210C1 (en)
YU (1) YU205590A (en)
ZA (1) ZA908725B (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943573A (en) * 1989-11-01 1990-07-24 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility
PH31245A (en) * 1991-10-30 1998-06-18 Janssen Pharmaceutica Nv 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives.
US5348960A (en) * 1992-04-03 1994-09-20 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyl oxy alkyl tetrazolyl piperidine derivatives
US5208237A (en) * 1992-04-03 1993-05-04 Bristol-Meyers Squibb Company 7-oxypropylsulfonamido-imidazo[4,5-b]quinolin-2-ones
US5196428A (en) * 1992-04-03 1993-03-23 Bristol-Myers Squibb Company Imidazo[4,5-b]qinolinyl oxy alkyl ureas
US5158958A (en) * 1992-04-03 1992-10-27 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyl oxy alkyl sulfonyl piperidine derivatives
US5552267A (en) * 1992-04-03 1996-09-03 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
TW593317B (en) * 1993-06-21 2004-06-21 Janssen Pharmaceutica Nv Positive cardiac inotropic and lusitropic pyrroloquinolinone derivatives
US5672622A (en) * 1994-04-21 1997-09-30 Berlex Laboratories, Inc. Treatment of multiple sclerosis
US6060501A (en) * 1994-06-02 2000-05-09 Schering Aktiengesellschaft Combined treatment of multiple sclerosis
WO1996005202A1 (en) * 1994-08-17 1996-02-22 Nippon Hypox Laboratories Inc. Imidazoquinoline derivative
US5798767A (en) * 1996-03-15 1998-08-25 Rendition, Inc. Method and apparatus for performing color space conversion using blend logic
SE9902987D0 (en) * 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
US20030186963A1 (en) * 2001-09-14 2003-10-02 Dorwald Florencio Zaragoza Substituted piperidines
US7064135B2 (en) 2001-10-12 2006-06-20 Novo Nordisk Inc. Substituted piperidines
EP2243776A1 (en) 2001-10-12 2010-10-27 High Point Pharmaceuticals, LLC Substituted piperidines and their use for the treatment of diseases related to the histamine H3 receptor
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (en) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド Neurogenesis through modulation of muscarinic receptors
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
US8227603B2 (en) * 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
US8299248B2 (en) * 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
EP2995619B1 (en) * 2006-08-02 2019-09-25 Cytokinetics, Inc. Certain chemical entities comprising imidazopyrimidines, compositions and methods
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US7851484B2 (en) * 2007-03-30 2010-12-14 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
MX354786B (en) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER and OTHER DISORDERS.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
GB0808968D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substitute quinazolines
GB0808967D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substitute quinazolines
GB0808952D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substituted quinazolines
GB0808947D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substituted quinazolines
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9580471B2 (en) 2011-03-01 2017-02-28 Synergy Pharmaceuticals, Inc. Process of preparing guanylate cyclase C agonists
BR112014000742A2 (en) 2011-07-13 2016-08-23 Andrew A Wolff als combination therapy
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP6606491B2 (en) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド Ultra high purity agonist of guanylate cyclase C, method for producing and using the same
JP6694385B2 (en) 2013-08-09 2020-05-13 アーデリクス，インコーポレーテッド Compounds and methods for inhibiting phosphate transport
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient
WO2024149378A1 (en) * 2023-01-13 2024-07-18 上海超阳药业有限公司 Quinolinone compound and naphthyridinone compound and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2190676A (en) * 1986-05-23 1987-11-25 Bristol Myers Co 2,3-dihydro-2-oxo-1h-imidazo(4,5-6)quinolinyl ether derivatives

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932407A (en) * 1973-11-19 1976-01-13 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones
NL7807507A (en) * 1977-07-25 1979-01-29 Hoffmann La Roche TRICYCLICAL CONNECTIONS.
US4490371A (en) * 1983-02-16 1984-12-25 Syntex (U.S.A.) Inc. N,N-Disubstituted-(2-oxo-1,2,3,5-tetrahydroimidazo-[2,1-B]quinazolinyl)oxyalkylamides
HU193409B (en) * 1984-02-15 1987-10-28 Syntex Inc Process for producing 2-square bracket -n-cyclohexyl-4-bracket-oxo-1,2,3,5-tetrahydro-imidazo-square bracket-2,1-b-square bracket closed-quinazolin-7-yl-bracket closed-oxy-alkqne-carboxamidyl-square bracket closed-alkan-acides
US4668686A (en) * 1985-04-25 1987-05-26 Bristol-Myers Company Imidazoquinoline antithrombrogenic cardiotonic agents
US4701459A (en) * 1986-07-08 1987-10-20 Bristol-Myers Company 7-amino-1,3-dihydro-2H-imidazo[4,5-b]quinolin 2-ones and method for inhibiting phosphodiesterase and blood platelet aggregation
US4943573A (en) * 1989-11-01 1990-07-24 Bristol-Myers Squibb Company Imidazo[4,5-b]quinolinyloxyalkanoic acid amides with enhanced water solubility

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2190676A (en) * 1986-05-23 1987-11-25 Bristol Myers Co 2,3-dihydro-2-oxo-1h-imidazo(4,5-6)quinolinyl ether derivatives

Also Published As

Publication number Publication date
AU6567990A (en) 1991-05-23
HU209305B (en) 1994-04-28
HUT56102A (en) 1991-07-29
EG19372A (en) 1994-12-30
IE903923A1 (en) 1991-05-08
CN1051359A (en) 1991-05-15
IL96167A (en) 1994-11-11
NO904689D0 (en) 1990-10-30
FI905326A0 (en) 1990-10-29
HU906977D0 (en) 1991-05-28
PT95765A (en) 1991-09-13
CA2027935A1 (en) 1991-05-02
MY105308A (en) 1994-09-30
YU205590A (en) 1992-09-07
IL96167A0 (en) 1991-07-18
EP0426180A2 (en) 1991-05-08
US4943573A (en) 1990-07-24
KR910009705A (en) 1991-06-28
CN1025999C (en) 1994-09-28
NO904689L (en) 1991-05-02
FI92697C (en) 1994-12-27
NO175531B (en) 1994-07-18
NO175531C (en) 1994-10-26
ZA908725B (en) 1991-07-31
NZ235868A (en) 1993-12-23
JPH03169880A (en) 1991-07-23
EP0426180A3 (en) 1992-01-08
IE61579B1 (en) 1994-11-16
OA09323A (en) 1992-09-15
RU2041210C1 (en) 1995-08-09
FI92697B (en) 1994-09-15

Similar Documents

Publication Publication Date Title
AU639033B2 (en) Imidazo(4,5-b)quinolinyloxyalkanoic acid amines with enhanced water solubility
CY2076B1 (en) N-[pyrrolo(2,3-d)pyrimidin-3-ylacyl]-glutamic acid derivatives
AU8171282A (en) 5 oxo-thiazolo(3,2-a)azepine-3-carboxylic acids
AU2587384A (en) Benzimidazole or imidazo (4,5-6) pyrioine derivatives
AU7149491A (en) Pyridazino{4,5-b}indolizines
AU7849387A (en) 2- or-3- aryl substituted imidazo(1,2-a)pyridines
AU2097988A (en) Imidazo (1,2-b) pyridazin-2-yl carbamate derivatives
AU8752482A (en) Imidazo (1,2-a)quinazolin-2-ones
ZA87143B (en) Pyrido(2,3-b)indoles
AU3820989A (en) 7-amino-3-beta-d-ribofuranosyl-3h-imidazo(4,5-b) pyridin-5-amine derivatives
PH24248A (en) Substituted 1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acids
AU630531B2 (en) Imidazo(4,5-c)pyridines as antiosteoporotic agents
DE3682244D1 (en) SUBSTITUTED DIHYDROIMIDAZO (1,2-A) CHINOXALINE DERIVATIVES.
KR960002228B1 (en) Water soluble monoazo naphtolcarbonic acid compound, the
NZ222080A (en) Imidazo(4,5-b)pyridin-2-one derivatives and pharmaceutical compositions
ZA873507B (en) Pyrazolo(3,4-b)pyridine derivatives,processes and intermediate stages for their preparation and their use as herbicides
AU5931486A (en) 6,7,8,9 - tetrahydropyrido (1,2 - a) indole derivatives
AU8286487A (en) 6,7,8,9-Tetrahydropyrido (1,2-a) indoles
ES2023410B3 (en) ACID 1,3,4,9-TETRAHIDROPIRAN 3,4-B] INDOL -1 SUBSTITUTED ACETICS.
GB8921635D0 (en) 3-pyrrolidinylthio-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid derivatives
GB8811237D0 (en) 3-pyrrolidinylthio-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid derivatives
AU591091B2 (en) Pyrazolo 1,5-a-pyridin-3-yl or benzimidazol-2-yl derivatives
AU1673388A (en) Imidazo (1,2-a)-pyrimidines
GB8909277D0 (en) 3-alkenyl-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid derivatives
AU3046389A (en) Novel 5,6-diphenyl-1,2-dihydroxy-3h-pyrrolo (1,2-a)pyrrole-1-carboxylic acid derivatives